Serum resistin levels in patients with type 2 diabetes mellitus and its relationship with body composition
Department of Physiology (29), College of Medicine, King Saud University, PO Box 2925, Riyadh 11461, Kingdom of Saudi Arabia. Saudi medical journal
(Impact Factor: 0.59).
To assess the relationships of resistin concentrations with body mass index (BMI), body fat mass, lean body mass, and body protein mass in patients with type 2 diabetes mellitus (DM).
This cross-sectional study was conducted in the Department of Physiology, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia from April 2008 to March 2011. A total of 229 subjects were selected for the study. Body composition was assessed by bioelectrical impedance analyzer. Parameters recorded included BMI, waist hip ratio (WHR), total body water, fat, protein, and lean body masses. Blood samples were analyzed for glucose, glycosylated hemoglobin (HbA1c), and resistin levels.
We found that BMI, WHR, fasting blood glucose, HbA1c, and resistin levels were significantly higher in diabetics compared to non-diabetic healthy individuals. Fat mass was significantly higher in diabetic patients compared with controls, while the difference for muscle mass and lean body mass was non-significant. A significant positive correlation was observed between plasma levels of resistin and fat mass in patients with DM (r=0.2824, p=0.0030).
Type 2 DM patients have significantly higher resistin levels that are positively correlated with body fat mass supporting the evidence that resistin plays an important role in the pathogenesis of obesity and insulin resistance.
Available from: Mohammed Attia
- "These studies involved larger numbers of subjects than previous studies which failed to show any such association and it may be that these earlier studies were underpowered to show such an association  . Habib concluded that type 2 DM patients have significantly higher resistin levels that are positively correlated with body fat mass supporting the evidence that resistin plays an important role in the pathogenesis of obesity and insulin resistance . Yin et al. have demonstrated the presence of resistin in saliva of T2DM and non-diabetic subjects. "
[Show abstract] [Hide abstract]
ABSTRACT: Obstructive sleep apnea (OSA) has been independently associated with cardiovascular diseases, including hypertension, coronary heart disease and heart failure. Also, it had a deleterious impact on renal function and a link to diabetes mellitus (DM) and insulin resistance. Resistin is new adipokine and may play a role in cardiac, diabetics and renal patients.
Available from: Jolanta Lewko
[Show abstract] [Hide abstract]
ABSTRACT: To determine the occurrence of symptoms of anxiety and depression in patients with type 2 diabetes, as well as to assess the relationship between the occurrence of symptoms of anxiety and depression, quality of life, and level of acceptance of illness of patients in northeastern Poland.
A cross-sectional study was conducted on 126 patients with type 2 diabetes in the Department of Endocrinology, Diabetes and Internal Diseases, Medical University of Bialystok, Bialystok, Poland from February 2010 to March 2011. Three questionnaires were administered: Hospital Anxiety and Depression Scale, Acceptance of Illness Scale, and SF-36v2 Scale.
Symptoms of anxiety were found in 30.4% of patients and depression in 32%, more often in women than men (20.6% versus 10.3% for anxiety and 22.2% versus 10.3% for depression). Multiple regression analysis revealed that 50% of variance on the illness acceptance scale affected the quality of life in relation to the general health PCS and MCS.
Symptoms of anxiety and depression adversely affect the degree of acceptance of illness and significantly lower the quality of life in patients with diabetes. Lowered quality of life is an important predictor of worse acceptance of illness by patients.
Available from: Omar M Al Nozha
[Show abstract] [Hide abstract]
To assess the plasma levels and relations of adipocytokines and biochemical bone markers in type 2 diabetes mellitus (T2DM) Saudi males with insulin resistance.
This case-control study included 80 overweight/obese males with T2DM on oral anti-diabetic medications recruited from the diabetic center and 40 healthy lean males of matched age. Measurements included fasting plasma glucose (FBG), fasting plasma insulin, serum calcium (Ca2 +), HbA1c, plasma adiponectin and resistance, serum bone-specific alkaline phosphatase (B-ALP), plasma osteocalcin (OC), and plasma osteoprotegerin (OPG). Waist and hip circumferences were measured. Body mass index, waist/hip ratio (WHR), and insulin resistance (HOMA-IR) were calculated.
Compared to the control group, diabetic patients showed significantly both lower adiponectin (p = 0.000) and Ca2 + (p = 0.000) but significantly higher resistance (p = 0.000), OC (p = 0.000), B-ALP level (p = 0.000) and OPG (p = 0.000). After multivariate adjustment in diabetic patients, resistance predicted OC, (beta = −0.30, p = 0.005), WC and resistance predicted Ca2+ (beta = −0.34, p = 0.035 and beta = −0.25, p = 0.033), adiponectin and resistance predicted B-ALP, (beta = −0.35, p = 0.010 and beta = 0.35, p = 0.004), and FBG, HOMA-IR and age predicted OPG, (beta = −0.66, p = 0.010, beta = 0.58, p = 0.024 and beta = 0.27, p = 0.031 respectively). Also, FBG, WHR and HOMA-IR predicted adiponectin (beta = −0.79, p = 0.001, beta = −0.60, p = 0.001 and beta = 0.80, p = 0.001 respectively), while OC and OPG predicted HbA1c (beta = −0.32, p = 0.007 and beta = 0.28, p = 0.016 respectively).
Uncontrolled T2DM Saudi males with insulin resistance have abnormal bone markers with unfavorable levels of adipocytokines. Strong associations between bone markers, adipocytokines, insulin resistance and metabolic control may suggest interaction in multiple direction feedback loops exacerbating hyperglycemia.
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.